MedTrace Logo

Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis

NCT07577466 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-05-11

No results posted yet for this study

Summary

Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months

Conditions

  • Amyloidosis Cardiac
  • Heart Failure
  • Cardiac MRI
  • Spectroscopic Analysis
  • Diagnosis
  • Phenotyping

Sponsors & Collaborators

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Malte Kelm, MD · Division of Cardiology, Pulmonary Disease and Vascular Medicine at University Hospital Duesseldorf

  • Amin Polzin, MD · Division of Cardiology, Pulmonary Disease and Vascular Medicine at University Hospital Duesseldorf

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07577466 on ClinicalTrials.gov